Drug Trial Radar · NCT05566041
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
292
Planned (sponsor's estimate)
Start
Aug 1, 2022
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Sciclone Pharmaceuticals (China) Co., Ltd.
- First posted
- Oct 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Conditions
- Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP DeviceDrug
RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy
Cisplatin/carboplatin plus etoposideDrug
Standard of care platinum doublet chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) and Overall Survival (OS)Time frame: Estimated up to 12 Months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
H. Lee Moffitt Cancer Center & Research Institute, Inc.
Tampa, Florida
The University of Kansas Cancer Center
Westwood, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.